JP6280033B2 - ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法 - Google Patents

ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法 Download PDF

Info

Publication number
JP6280033B2
JP6280033B2 JP2014520341A JP2014520341A JP6280033B2 JP 6280033 B2 JP6280033 B2 JP 6280033B2 JP 2014520341 A JP2014520341 A JP 2014520341A JP 2014520341 A JP2014520341 A JP 2014520341A JP 6280033 B2 JP6280033 B2 JP 6280033B2
Authority
JP
Japan
Prior art keywords
alkoxy
alkyl
nitro
hydroxy
membered ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014520341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524918A (ja
JP2014524918A5 (enExample
Inventor
ロバーツ,エル.ジャクソン
アマーナス,ベンカタラマン
ジー. ハリソン,ディヴィッド
ジー. ハリソン,ディヴィッド
キラボ アネット
キラボ アネット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2014524918A publication Critical patent/JP2014524918A/ja
Publication of JP2014524918A5 publication Critical patent/JP2014524918A5/ja
Application granted granted Critical
Publication of JP6280033B2 publication Critical patent/JP6280033B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014520341A 2011-07-12 2012-07-12 ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法 Active JP6280033B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506848P 2011-07-12 2011-07-12
US61/506,848 2011-07-12
PCT/US2012/046549 WO2013010034A2 (en) 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Publications (3)

Publication Number Publication Date
JP2014524918A JP2014524918A (ja) 2014-09-25
JP2014524918A5 JP2014524918A5 (enExample) 2015-09-03
JP6280033B2 true JP6280033B2 (ja) 2018-02-14

Family

ID=47506934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014520341A Active JP6280033B2 (ja) 2011-07-12 2012-07-12 ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法

Country Status (13)

Country Link
US (4) US10975033B2 (enExample)
EP (1) EP2731597B1 (enExample)
JP (1) JP6280033B2 (enExample)
KR (2) KR20140050661A (enExample)
CN (2) CN103796648B (enExample)
AU (1) AU2012281061B2 (enExample)
BR (1) BR112014000810A8 (enExample)
CA (1) CA2844150C (enExample)
ES (1) ES2970814T3 (enExample)
HU (1) HUE065757T2 (enExample)
MX (1) MX383365B (enExample)
PL (1) PL2731597T3 (enExample)
WO (1) WO2013010034A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130018478A (ko) * 2011-08-09 2013-02-25 주식회사 엘지화학 신규한 구조의 이차전지 팩
US10166248B1 (en) * 2015-12-21 2019-01-01 Vanderbilt University Methods of preventing platelet activation
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
CA3030036A1 (en) * 2016-07-06 2018-01-11 Vanderbilt University Use of scavengers of reactive gamma-ketoaldehydes to extend cell lifespan and healthspan
PL3481505T3 (pl) * 2016-07-07 2026-01-26 Vanderbilt University Zapobieganie i leczenie migotania/trzepotania przedsionków za pomocą środków wychwytujących gamma-ketoaldehyd
EP3510014B8 (en) * 2016-09-06 2026-07-29 MTI Biotech, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nash or ald
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
EP4385576A3 (en) * 2016-11-15 2024-09-04 Vanderbilt University Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
HUE066390T2 (hu) 2017-04-27 2024-07-28 Univ Vanderbilt Eljárások ateroszklerózis kezelésére gamma-ketoaldehid-szkevendzserekkel
US20210023032A1 (en) 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
WO2019050967A1 (en) * 2017-09-05 2019-03-14 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USING GAMMA-KETOALDEHYDE SENSORS TO TREAT, PREVENT, OR IMPROVE LIVER FIBROSIS
CN109836341B (zh) * 2017-11-28 2021-08-27 江阴技源药业有限公司 一种水杨胺醋酸盐的制备方法
US20200197323A1 (en) * 2018-12-21 2020-06-25 Vanderbilt University Methods for suppressing accumulation of reflux-induced protein adducts
US20230069820A9 (en) * 2019-09-24 2023-03-02 Vanderbilt University Use of 2-hydroxybenzylamine for the treatment of systemic lupus
WO2021154877A1 (en) * 2020-01-27 2021-08-05 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof
CN118652245B (zh) * 2024-08-21 2024-11-12 首都医科大学附属北京儿童医院 一种化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740439A (en) * 1968-06-24 1973-06-19 Ciba Geigy Corp Treating hypertension with beta-aminoalkane carboxylic acids
US3794734A (en) 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US4123537A (en) * 1977-05-26 1978-10-31 Merck & Co., Inc. 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
AU5659796A (en) 1995-05-19 1996-11-29 Kissei Pharmaceutical Co. Ltd. 2-hydroxyphenylalkylamine derivatives and maillard reaction inhibitors
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
ATE333868T1 (de) 2000-11-02 2006-08-15 Univ South Carolina Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US7705054B1 (en) * 2004-10-20 2010-04-27 Vanderbilt University Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases
EP2207555B1 (en) * 2007-10-05 2013-07-24 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema
KR100973343B1 (ko) * 2008-02-01 2010-07-30 롯데칠성음료주식회사 기호성이 우수한 혼합차 조성물 및 그 제조방법
CN101305759B (zh) * 2008-06-19 2011-09-07 成都大学 一种苦荞保健茶及其制备方法
CN101843671A (zh) * 2009-03-25 2010-09-29 王文祥 苦荞托毒丸及其制备方法
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
CN101606986A (zh) * 2009-07-29 2009-12-23 李钢 一种具有降糖作用的组合物及其药物

Also Published As

Publication number Publication date
CA2844150C (en) 2019-09-03
BR112014000810A2 (pt) 2017-06-13
JP2014524918A (ja) 2014-09-25
MX383365B (es) 2025-03-13
EP2731597A2 (en) 2014-05-21
US10975033B2 (en) 2021-04-13
AU2012281061A1 (en) 2014-02-20
PL2731597T3 (pl) 2024-04-29
MX2014000515A (es) 2014-03-27
US20250034093A1 (en) 2025-01-30
ES2970814T3 (es) 2024-05-30
US20140256774A1 (en) 2014-09-11
KR20140050661A (ko) 2014-04-29
AU2012281061B2 (en) 2017-08-03
CN103796648B (zh) 2019-10-25
KR102050700B1 (ko) 2019-11-29
CN103796648A (zh) 2014-05-14
WO2013010034A3 (en) 2013-03-28
HUE065757T2 (hu) 2024-06-28
BR112014000810A8 (pt) 2022-11-29
WO2013010034A2 (en) 2013-01-17
EP2731597B1 (en) 2023-12-20
CA2844150A1 (en) 2013-01-17
KR20190069607A (ko) 2019-06-19
CN111494352A (zh) 2020-08-07
EP2731597C0 (en) 2023-12-20
US20250214939A1 (en) 2025-07-03
EP2731597A4 (en) 2015-04-08
US20210261508A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US20250214939A1 (en) Method for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
US20080214531A1 (en) Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipdemia
EA015783B1 (ru) Производные имидазола, композиции и их применение в терапии
US12060379B2 (en) Plasmalogen derivatives
JP2024063122A (ja) 加齢に関連する状態の診断及び治療のための組成物及び方法
WO2012047656A1 (en) Lipid a analog compositions
TW202337456A (zh) Gm2神經節苷脂症之治療
JP2022046654A (ja) γ-ケトアルデヒドスカベンジャーによるアテローム性動脈硬化症の治療方法
JP2023504194A (ja) インスリン耐性における使用方法のための治療化合物
EP1277743A1 (en) Oxa(thia)zolidine derivative and anti-inflammatory drug
CN111344016B (zh) 用于抑制胆碱向三甲胺(tma)的转化的方法
US20220370411A1 (en) EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS
US20050113443A1 (en) Modulation of airway inflammation in patients with cystic fibrosis and related diseases
HK40023703A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
EP3618834B1 (en) Functionalized saccharides as anti-inflammatory agents
JP6353159B2 (ja) Tlr非依存性低分子アジュバント
HK1191859A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
HK1191859B (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
CN111163765A (zh) 用于抑制胆碱向三甲胺(tma)的转化的方法
US20230355549A1 (en) Method of preventing kidney injury disruption of intestinal lymphatics
US20210170000A1 (en) Larval preparation of Heligmosomoides polygyrus bakeri as well as methods of making it and uses thereof
US10251852B2 (en) Composition and methods for treatment of lung disorders characterized by cholesterol dysregulation
JP2004196660A (ja) 糖脂質代謝異常症の治療薬
KR20150013122A (ko) 염증을 치료하고 면역 반응을 조절하기 위한 화합물 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180118

R150 Certificate of patent or registration of utility model

Ref document number: 6280033

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250